Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Biology

Cancer Oncology

Medicine

Epidemiology

Internal Medicine

Show all topics

DOI

10.1016/s1470-2045(13)70095-0

Other Formats

PDF